Trial Profile

A Pilot Study of INCB039110 (Itacitinib) for the Treatment of Steroid Refractory Chronic Graft-Versus-Host Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itacitinib (Primary) ; Corticosteroids; Immunosuppressants
Indications Graft-versus-host disease
Focus Therapeutic Use

Most Recent Events

06 Nov 2023 Status changed from active, no longer recruiting to discontinued.
14 Mar 2023 Status changed from recruiting to active, no longer recruiting.
14 Sep 2021 Treatments section is updated to increase the duration of administering Itacitinib from 12 months to 24 months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com